Provexis Plc (PXS) Ordinary 0.1p
Provexis plc is engaged in developing, licensing and selling the proprietary, scientifically proven Fruitflow heart-health functional food ingredient. Fruitflow is a natural extract from tomatoes, which has been shown in human trials to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can lead to heart attack and stroke. The extract is available in two formats, a syrup and a spray-dried powder and can be included in a range of food, beverage, and dietary supplement formats. Fruitflow is a highly concentrated form of bioactives that is lycopene-free and contains over 30 known anti-platelet compounds. The syrup and powder versions of Fruitflow are GRAS in the United States. The Company also offers Fruitflow+ Omega-3, a dietary supplement product. The Company sells its Fruitflow+ Omega-3 dietary supplement product direct to consumers and serves its Chinese cross-border e-commerce distributor for this product in China.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.